Smith & Nephew plc (ADR) (NYSE:SNN)

CAPS Rating: 4 out of 5

The Company is a global business engaged in the development, manufacture and marketing of medical devices in the sectors of orthopaedic reconstruction, orthopaedic trauma and clinical therapies, endoscopy and advanced wound management.

Results 1 - 17 of 17

Recs

0
Member Avatar gunterle (66.21) Submitted: 9/5/2012 11:30:40 AM : Outperform Start Price: $51.33 SNN Score: +15.79

signal

Recs

0
Member Avatar pdoli (29.60) Submitted: 4/18/2011 9:03:43 AM : Outperform Start Price: $50.84 SNN Score: +6.38

http://bit.ly/fXxgVO

Recs

0
Member Avatar rd80 (98.55) Submitted: 2/19/2011 3:18:08 PM : Outperform Start Price: $44.43 SNN Score: +18.08

Following hip replacement surgery last year, it seemed appropriate that a look at companies making artificial joints would be a good way to get back in the stock picking and writing game.

I dug a little into the future growth prospects for joint replacement surgery and briefly profiled four of the top device manufacturers. All four looked like reasonable investments, but not all for the same reason.
http://www.fool.com/investing/general/2010/11/09/these-joints-rock.aspx

Of the four, I thought SNN was the best shot for a green thumb and, so far, its working out pretty well.

Recs

0
Member Avatar pentasa11 (< 20) Submitted: 1/28/2011 5:49:37 PM : Outperform Start Price: $51.62 SNN Score: +1.29

Possible takeover target but also a very good stock in a growing industry . It's products could be better then it's competitors .

Recs

0
Member Avatar RXDOC73 (99.34) Submitted: 1/10/2011 8:00:13 AM : Outperform Start Price: $52.93 SNN Score: -4.11

Will eventually be a buyout target in the 2011 consolidation wave.

Recs

0
Member Avatar bartleyrc (86.81) Submitted: 8/4/2010 3:51:08 AM : Outperform Start Price: $41.28 SNN Score: +18.07

Smith and Nephew has a new type of metal alloy in the articulating surfaces of their new hip and knee implants that, according to peer-reviewed studies will withstand enough wear cycles without spicule formation and subsequest implant loosening to last for 30 years!!! The top Zimmer joint reps (currently #1 in market share in the Midwest) are defecting to Smith and Nephew!! This is HUGE!!! STRONG BUY on SNN NOW!!!!!

Recs

0
Member Avatar sk8jeff1 (90.20) Submitted: 5/23/2009 9:53:06 AM : Outperform Start Price: $32.73 SNN Score: +18.52

Smith and Nephew is a large and safe company. SNN is near a 52 week low. Nothing about SNN itself has caused this drop in stock price. The costs of lending, oil prices and the generally poor economy have caused this stock to drop. SNN has a couple of new products in the final stages of development that will be used by orthopedic surgeons within the next year.SNN is widely regarded in the medical community for making safe, reliable and innovative products. They consult with and are counseled by physicians in Boston when making these products. There is no reason to believe their new products will not be just as successful as their past products. Get this stock near its 52 week low. It will pay you dividends and the price will grow.

Recs

0
Member Avatar ddberg (25.64) Submitted: 1/28/2009 11:07:43 AM : Outperform Start Price: $32.42 SNN Score: +14.94

Aging population that's living longer, exponential growth in orthopedic procedures, and a strong presence in those operating rooms.

Recs

1
Member Avatar nbpt100 (69.13) Submitted: 7/29/2008 12:59:50 PM : Outperform Start Price: $48.91 SNN Score: +1.49

Yes SNN will outperform the S&P 500 but don't expect huge returns. On the other hand the downward potential is not that much. It is a good investment based on the risk return ratio. This is a conservative company with a 1% dividend. Most of their profit comes from disposible medical devices which is a strong and steady business but slow single digit growth. Their wound management business is a very slow grower and I would not be surprised if they sold it. The big growth is in the orthapedics area which should deliver double digit growth. That is what everyone is focused on. The Stock price took a big hit earlier this year because of an impropropriety in Greece. The company has been buying back stock which does help the shareholders. Once they get over this impropriety in Greece the stock should return to outperforming the market, but don't expect a double in 2 years. This is a good investment for a more risk averse individual. It is a buy at todays prices.

Recs

0
Member Avatar Jstaple7 (< 20) Submitted: 2/26/2008 4:53:29 PM : Outperform Start Price: $58.93 SNN Score: -12.71

Great growth stock as the ortho company has increased market share each year. They continue to pressure leading competitors Zimmer and Stryker and are poised to overtake Zimmer in 2010.

They have addressed their inventory concerns from 2006 and are continuing to implement full lean processes. The SAP conversion from previously outdated BPCS will only aid in the management of their inventories.

Recs

0
Member Avatar TrackMasterTrack (< 20) Submitted: 10/11/2007 2:27:44 AM : Outperform Start Price: $55.85 SNN Score: +11.35

bound to out pace

Recs

2
Member Avatar Bizoid (61.16) Submitted: 6/19/2007 11:16:42 AM : Outperform Start Price: $54.87 SNN Score: +9.79

I like joints.

Recs

2
Member Avatar NetscribeMedDevs (92.33) Submitted: 3/21/2007 8:49:26 AM : Outperform Start Price: $56.15 SNN Score: -4.72

Smith & Nephew develops and markets advanced medical devices for orthopedics, endoscopy, and wound management sectors worldwide. The company operates thorough its Global Business Units which include Orthopaedic Reconstruction, Orthopaedic Trauma & Clinical Therapies, Endoscopy and Advanced Wound Management. Through these business units and a separate indirect market unit the compene operates in 33 countries around the world.

The total revenues grew by 15% for the fourth quarter of the fiscal 2006 as compared to the same period in 2005. The company is a market leader in providing innovative products especially in reconstruction. The slate of new products the company introduced last year, plus the additions this year, gives it a strong platform for growth. Products like BHR and JOURNEY were only introduced halfway through the year, so it is expected to benefit for the full-year 2007.

The company is looking forward to seek value enhancing acquisitions that relate to unique or additive technologies and products and to improve its channels to market. In line with this strategy the company has recently acquired Plus Orthopedics. Plus is one of the top players in hips in Germany which is the world’s third largest orthopedics market and they also are a strong player in knees in Germany as well and their manufacturing is based both in Switzerland and in China. This acquisition is expected to strengthen the company’s distribution channels and increase leverage in its sales channels both in Europe and Asia.

Looking at the company’s market leadership in all of its business units and its strategy to break into new markets will help the company grow in a rapid pace. It is expected that this will not only make the company’s performance strong but also help the stockholders reap maximum profits out of their holdings.

Recs

1
Member Avatar momoose1 (73.87) Submitted: 1/13/2007 12:58:55 PM : Outperform Start Price: $47.33 SNN Score: +22.01

continues to be the fastest growing ortho recon company. ahead of the competition with hip resurfacing product and alternate bearings for both hips & knees.

Recs

0
Member Avatar phdche (47.31) Submitted: 12/22/2006 7:28:10 AM : Outperform Start Price: $46.54 SNN Score: +23.34

Potential for buy out by private firm

Recs

2
Member Avatar ROXYMUSIC1 (69.03) Submitted: 12/6/2006 8:34:52 PM : Outperform Start Price: $42.13 SNN Score: +40.94

UK based company that engages in the development and manufacture of medical devices and equipment for hip, knee, and shoulder joint replacement. Excellent run company. Nice earnings. Recommended.

Recs

3
Member Avatar Fuma102 (91.95) Submitted: 11/24/2006 1:04:54 PM : Outperform Start Price: $42.06 SNN Score: +38.91

really, really, really like this stock. little debt, underfollowed, and in a growing field. pays a slight div as well. will be adding to my real port on any price dips.

Results 1 - 17 of 17

Featured Broker Partners


Advertisement